| Description | Rabeximod is a potent immunomodulator that reduces the severity of autoimmune diseases in rat models. Rabeximod inhibits arthritis in a time-dependent manner by stimulating TLR2 and TLR4 downstream to block the activation of inflammatory cells, most likely macrophages. Rabeximod effectively reduces brain antigen presentation in mice during anti-inflammatory therapy for traumatic brain injury. |
| In vivo | Rabeximod efficiently prevented arthritis during the time window when TLR2 or TLR4 ligands activate inflammatory macrophages. The effect operated downstream of TLR activation as Rabeximod was highly therapeutic in CAIA enhanced through TLR2 stimuli in TLR4 deficient mice. In addition, it was found that the arthritis ameliorating effect of Rabeximod was time dependent, since inhibition of tumour necrosis factor α production from macrophages in vitro was more pronounced if administered close to stimulation.[1] |
| Synonyms | ROB-803 |
| molecular weight | 409.91 |
| Molecular formula | C22H24ClN5O |
| CAS | 872178-65-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: Slightly soluble |
| References | 1. Hultqvist M, et al. Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Ann Rheum Dis. 2010;69(8):1527-1532. 2. Hultqvist M, et al. Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Ann Rheum Dis. 2010 Aug;69(8):1527-32. 3. Giusti P, et al. The novel anti-rheumatic compound Rabeximod impairs differentiation and function of human pro-inflammatory dendritic cells and macrophages. Immunobiology. 2011 Jan-Feb;216(1-2):243-50. 4. Hultqvist M, et al. The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders. Ann Rheum Dis. 2009 Jan;68(1):130-5. |